MX2021009170A - Cristal de compuesto de diariltiohidantoina. - Google Patents

Cristal de compuesto de diariltiohidantoina.

Info

Publication number
MX2021009170A
MX2021009170A MX2021009170A MX2021009170A MX2021009170A MX 2021009170 A MX2021009170 A MX 2021009170A MX 2021009170 A MX2021009170 A MX 2021009170A MX 2021009170 A MX2021009170 A MX 2021009170A MX 2021009170 A MX2021009170 A MX 2021009170A
Authority
MX
Mexico
Prior art keywords
crystal
diarylthiohydantoin compound
preparation
diarylthiohydantoin
compound
Prior art date
Application number
MX2021009170A
Other languages
English (en)
Inventor
Li Zhang
Fei Liu
Ting Wang
Xin Tian
Chunli Shen
Shenglin Chen
Yuying Guo
Jiahu Wu
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2021009170A publication Critical patent/MX2021009170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente solicitud pertenece al campo de la medicina y en particular se refiere a un cristal de un compuesto de diariltiohidantoína que tiene una estructura de la siguiente fórmula (I), a un procedimiento de preparación del mismo y a su uso en la preparación de medicamentos para tratar enfermedades relacionadas que están mediadas por andrógenos. (ver Fórmula).
MX2021009170A 2019-02-01 2020-01-22 Cristal de compuesto de diariltiohidantoina. MX2021009170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910104953 2019-02-01
PCT/CN2020/073821 WO2020156448A1 (zh) 2019-02-01 2020-01-22 二芳基硫代乙内酰脲化合物结晶

Publications (1)

Publication Number Publication Date
MX2021009170A true MX2021009170A (es) 2021-09-10

Family

ID=71840904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009170A MX2021009170A (es) 2019-02-01 2020-01-22 Cristal de compuesto de diariltiohidantoina.

Country Status (12)

Country Link
US (1) US20220009925A1 (es)
EP (1) EP3919493A4 (es)
JP (1) JP7464613B2 (es)
KR (1) KR20210124333A (es)
CN (1) CN113439083B (es)
AU (1) AU2020214494A1 (es)
BR (1) BR112021015122A2 (es)
CA (1) CA3128074A1 (es)
IL (1) IL285219A (es)
MX (1) MX2021009170A (es)
SG (1) SG11202108300VA (es)
WO (1) WO2020156448A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032644B (zh) 2017-08-07 2021-08-10 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
WO2021143925A1 (zh) * 2020-01-19 2021-07-22 正大天晴药业集团股份有限公司 作为ar拮抗剂的二芳基硫代乙内酰脲化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104105690A (zh) * 2011-12-05 2014-10-15 诺华股份有限公司 作为雄激素受体拮抗剂的环状尿素衍生物
CN103804358B (zh) * 2012-11-14 2016-06-29 上海医药集团股份有限公司 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015018356A1 (zh) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
CN104341352A (zh) * 2013-08-09 2015-02-11 南京衡杰生物科技有限公司 作为雄激素受体拮抗剂的二芳基乙内酰脲化合物及其应用
CN104341342B (zh) * 2014-10-23 2016-04-13 中国电子科技集团公司第四十六研究所 一种高产率、高纯度的dast源粉合成工艺
CN106146474A (zh) * 2015-04-24 2016-11-23 成都贝斯凯瑞生物科技有限公司 硫代咪唑二酮和咪唑二酮类化合物及其用途
CA3030181A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
CN111032644B (zh) * 2017-08-07 2021-08-10 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物

Also Published As

Publication number Publication date
CA3128074A1 (en) 2020-08-06
EP3919493A1 (en) 2021-12-08
JP2022518605A (ja) 2022-03-15
WO2020156448A1 (zh) 2020-08-06
EP3919493A4 (en) 2022-11-16
CN113439083A (zh) 2021-09-24
KR20210124333A (ko) 2021-10-14
BR112021015122A2 (pt) 2021-09-28
CN113439083B (zh) 2023-01-24
IL285219A (en) 2021-09-30
AU2020214494A1 (en) 2021-09-16
JP7464613B2 (ja) 2024-04-09
SG11202108300VA (en) 2021-08-30
US20220009925A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
PH12019502436A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX2019001481A (es) Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo.
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
MX2015003021A (es) Derivados de acido glicirretinico y metodos de uso de los mismos.
NZ607580A (en) N-heteroaryl compounds
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
MX2021011823A (es) Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
BR112022005660A2 (pt) Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos.
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
MX2021009170A (es) Cristal de compuesto de diariltiohidantoina.
MX348961B (es) Compuestos de aminoindano y su uso en el tratamiento del dolor.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue